[1]Torimura T, Iwamoto H. Treatment and the prognosis of hepatocellular carcinoma in Asia[J]. Liver Int, 2022,42(9): 2042-2054.
[2]Yang J D, Heimbach J K. New advances in the diagnosis and management of hepatocellular carcinoma[J]. BMJ, 2020, 371:m3544.
[3]Zhao C, Nguyen M H. Hepatocellular carcinoma screening and surveillance: practice guidelines and real-life practice[J]. J Clin Gastroenterol, 2016, 50(2): 120-133.
[4]Liu R, Ma Y, Guo T, et al. Identification, biogenesis, function, and mechanism of action of circular RNAs in plants[J]. Plant Commun, 2023, 4(1): 100430.
[5]屈潇,秦环龙. miR-150在肿瘤发生发展中作用机制研究进展[J].中国医药导报, 2017, 14(32): 4.
[6]Sun W, Zhang Z, Wang J, et al. MicroRNA-150 suppresses cell proliferation and metastasis in hepatocellular carcinoma by inhibiting the GAB1-ERK axis[J]. Oncotarget, 2016, 7(10): 11595-11608.
[7]Liu Y, Tan J, Ou S,et al. MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway[J]. Invest New Drugs, 2020, 38(1): 60-69.
[8]Youssef S S, Elfiky A, Nabeel M M, et al. Assessment of circulating levels of microRNA-326, microRNA-424, and microRNA-511 as biomarkers for hepatocellular carcinoma in Egyptians[J]. World J Hepatol, 2022, 14(8): 1562-1575.
[9]de la Cruz-Ojeda P, Schmid T, Boix L, et al. miR-200c-3p, miR-222-5p, and miR-512-3p constitute a biomarker signature of sorafenib effectiveness in advanced hepatocellular carcinoma[J]. Cell, 202, 11(17): 2673.
[10]Zhou T, Wu L, Ma N, et al. LncRNA PART1 regulates colorectal cancer via targeting miR-150-5p/miR-520h/CTNNB1 and activating Wnt/β-catenin pathway[J]. Int J Biochem Cell Biol, 2020, 118: 105637.
[11] Lederer M, Bley N, Schleifer C, et al. The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer[J]. Semin Cancer Biol, 2014, 29: 3-12.
[12]胡烨,许小青,王冰晶,等.MiR-142-5p通过靶向IGF2BP3调控多柔比星诱导的肝癌细胞凋亡[J].中国肿瘤生物治疗杂志, 2017, 24(6): 7.
[13]Wang F, Ying H Q, He B S, et al. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway[J]. Oncotarget, 2015, 6(10): 7899-7917.
|